Argenica Therapeutics Limited researches and develops a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG007, a neuroprotective peptide candidate in pre-clinical trials for use in the protection of brain tissue against damage during a stroke. The company was incorporated in 2019 and is based in Nedlands, Australia.